Aug 2022 Articles

Articles
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week
Tsimikas S, Marcovina SM
Journal:
J Am Coll Cardiol

First published: August 30, 2022 DOI: 10.1016/j.jacc.2022.06.019
View
- Share
Articles
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B
Bonaca MP, Morrow DA, Bergmark BA, et al.
Journal:
Circulation

First published: August 30, 2022 DOI: 10.1161/CIRCULATIONAHA.122.059325
View
- Share
Articles
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Cholesterol Treatment Trialists’ Collaboration
Journal:
The Lancet

First published: August 29, 2022 DOI: 10.1016/S0140-6736(22)01545-8
View
- Share
Articles
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Kronenberg F, Mora S, Stroes ESG, et al.
Journal:
Eur Heart J

First published: August 29, 2022 DOI: 10.1093/eurheartj/ehac361
View
- Share
Articles
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
O’Donoghue ML, Giugliano RP, Wiviott SD, et al.
Journal:
Circulation

First published: August 29, 2022 DOI: 10.1161/CIRCULATIONAHA.122.061620
View
- Share
Articles
Statin intolerance: time to stop letting it get in the way of treating patients
Banach Maciej
Journal:
The Lancet

First published: August 29, 2022 DOI: 10.1016/S0140-6736(22)01643-9
View
- Share
Articles
Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey
Gupta K, Kakar TS, Jain V, et al.
Journal:
Prog Cardiovasc Dis

First published: August 28, 2022 DOI: 10.1016/j.pcad.2022.08.007
View
- Share
Articles
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Wilson DP, Jacobson TA, Jones PH, et al.
Journal:
Journal of Clinical Lipidology

First published: August 28, 2022 DOI: 10.1016/j.jacl.2022.08.007
View
- Share
Articles
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
Lopez-Jimenez F, Almahmeed W, Bays H, et al.
Journal:
Eur J Prev Cardiol

First published: August 25, 2022 DOI: 10.1093/eurjpc/zwac187
View
- Share
Articles
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms
Orringer CE, Grant JK, Tokgozoglu L
Journal:
Curr Atheroscler Rep

First published: August 24, 2022 DOI: 10.1007/s11883-022-01059-x
View
- Share
Articles
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Mangione CM, Barry MJ, et al.
Journal:
JAMA

First published: August 23, 2022 DOI: 10.1001/jama.2022.13044
View
- Share
Articles
Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018
Aggarwal R, Bhatt DL, Rodriguez F, et al.
Journal:
JAMA

First published: August 23, 2022 DOI: 10.1001/jama.2022.12567
View
- Share

1 2

Aug 2022 Articles

Articles

Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week

Tsimikas S, Marcovina SM

Articles

Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B

Bonaca MP, Morrow DA, Bergmark BA, et al.

Articles

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Cholesterol Treatment Trialists’ Collaboration

Articles

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

Kronenberg F, Mora S, Stroes ESG, et al.

Articles

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease

O’Donoghue ML, Giugliano RP, Wiviott SD, et al.

Articles

Statin intolerance: time to stop letting it get in the way of treating patients

Banach Maciej

Articles

Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey

Gupta K, Kakar TS, Jain V, et al.

Articles

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Wilson DP, Jacobson TA, Jones PH, et al.

Articles

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Lopez-Jimenez F, Almahmeed W, Bays H, et al.

Articles

A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms

Orringer CE, Grant JK, Tokgozoglu L

Articles

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force, Mangione CM, Barry MJ, et al.

Articles

Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018

Aggarwal R, Bhatt DL, Rodriguez F, et al.

Articles

Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week

Tsimikas S, Marcovina SM

Share

Articles

Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B

Bonaca MP, Morrow DA, Bergmark BA, et al.

Share

Articles

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Cholesterol Treatment Trialists’ Collaboration

Share

Articles

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

Kronenberg F, Mora S, Stroes ESG, et al.

Share

Articles

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease

O’Donoghue ML, Giugliano RP, Wiviott SD, et al.

Share

Articles

Statin intolerance: time to stop letting it get in the way of treating patients

Banach Maciej

Share

Articles

Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey

Gupta K, Kakar TS, Jain V, et al.

Share

Articles

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Wilson DP, Jacobson TA, Jones PH, et al.

Share

Articles

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Lopez-Jimenez F, Almahmeed W, Bays H, et al.

Share

Articles

A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms

Orringer CE, Grant JK, Tokgozoglu L

Share

Articles

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force, Mangione CM, Barry MJ, et al.

Share

Articles

Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018

Aggarwal R, Bhatt DL, Rodriguez F, et al.

Share